However, they found that Mbnl1−/−/Mbnl2+/− were viable (albeit with reduced survival), smaller in size, and had increased myotonia, weakness, and severe myopathy by 8–12 weeks of age. This evidence concerns the gene MBNL2 and Myotonia.